Trials / Completed
CompletedNCT04395911
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- SeaStar Medical · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Selective Cytopheretic Device (SCD) treatments will improve survival in patients testing positive for COVID-19 infection diagnosed with Acute Kidney Injury (AKI) or ARDS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | SCD | cytopheretic device |
Timeline
- Start date
- 2020-09-10
- Primary completion
- 2021-07-05
- Completion
- 2021-07-21
- First posted
- 2020-05-20
- Last updated
- 2021-08-05
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04395911. Inclusion in this directory is not an endorsement.